4D pharma plc
(the "Company" or "4D pharma")
Result of AGM
At the annual general meeting of 4D pharma plc (AIM: DDDD; Nasdaq: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products, held earlier today, all resolutions put to shareholders were duly passed.
The full text of each resolution was included in the notice of the meeting, which was posted to shareholders on 20 May 2022, and is available on the Company's website www.4dpharmaplc.com.
The results for the resolutions will shortly be available on the Shareholder Information section of the Company's website, www.4dpharmaplc.com.
Ahead of the meeting, the following statement was made:
"On 24 June 2022, David Pike and James Clark of Interpath Advisory were appointed as administrators of the Company. The administrators have had no oversight of or involvement in the preparation or convening of this Annual General Meeting nor in any of the materials circulated to the Company's shareholders in advance of this Annual General Meeting [which for the avoidance of doubt shall include, [but not be limited to], the Notice of Annual General Meeting dated 25 May 2022 ("AGM Notice") or any enclosures or documents referred to therein.]
Therefore, the administrators make no statement or representation in respect of any of the matters raised or discussed in advance of or during this Annual General Meeting. The administrators make no comment whatsoever in respect of the AGM Notice including any information on the Company or its equity securities, any statements of belief or intent by the Directors, the resolutions proposed (including any recommendations given by the Directors in relation to them or reasoning for the resolutions) or which may be passed at this meeting, or any answers given by the Directors to questions raised by shareholders in connection with this Annual General Meeting. The Administrators intend to take legal advice as to whether any resolutions that are passed at the meeting are, in all circumstances, legally valid. The administrators make no comment whatsoever on the appropriateness of the convening of the Annual General Meeting or the manner in which the Annual General Meeting is conducted. To the extent that the implementation of any resolutions passed at this Annual General Meeting requires the exercise of a management power pursuant to paragraph 64(1) of Schedule B1 of the Insolvency Act 1986, the administrators have had no opportunity to consider whether such implementation is appropriate for the purposes of the administration and therefore provide no consent in this regard."
| For further information please contact: | ||||||||||||||||||||
|
About 4D pharma
4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D pharma has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.
4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has six clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA® (pembrolizumab) in solid tumors, a Phase II clinical trial of MRx0518 in combination with BAVENCIO® (avelumab) in the first-line maintenance setting for urothelial carcinoma, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, and Blautix® in irritable bowel syndrome (IBS) which has completed a successful Phase II trial. A Phase I study of MRx0005 and MRx0029 in patients with Parkinson's disease is expected to commence in 2022. Additional preclinical-stage programs include candidates for CNS disease, immune-inflammatory conditions and cancer. The Company has a research collaboration with MSD (Merck & Co., Inc., Kenilworth, NJ, USA), to discover and develop Live Biotherapeutics for vaccines.
For more information, refer to https://www.4dpharmaplc.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.